Edgar Lomax Co. VA Sells 628,910 Shares of Pfizer Inc. $PFE

Key Points

• Edgar Lomax Co. VA reduced its holdings in Pfizer Inc. by 43.8% to 805,400 shares, valued at approximately $20.41 million according to a recent SEC filing.
• Multiple institutional investors have recently increased their stakes in Pfizer, with total institutional ownership now at 68.36% of the company's stock.
• Pfizer's quarterly earnings exceeded expectations, reporting $0.78 EPS and $14.65 billion in revenue, marking a 10.3% year-over-year increase.

Edgar Lomax Co. VA lessened its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 43.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 805,400 shares of the biopharmaceutical company's stock after selling 628,910 shares during the period. Edgar Lomax Co. VA's holdings in Pfizer were worth $20,409,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Bessemer Group Inc. increased its stake in Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after acquiring an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK increased its stake in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new position in Pfizer in the first quarter valued at approximately $8,283,000. Alta Advisers Ltd increased its stake in Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after acquiring an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC increased its stake in Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after acquiring an additional 10,051 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.9%

Pfizer stock traded up $0.2250 during mid-day trading on Tuesday, hitting $25.2950. 29,134,298 shares of the stock were exchanged, compared to its average volume of 45,102,056. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm's fifty day simple moving average is $24.64 and its two-hundred day simple moving average is $24.41. The stock has a market capitalization of $143.82 billion, a price-to-earnings ratio of 13.45, a PEG ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the company posted $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. TD Cowen cut their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Leerink Partners cut their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.